Resistance to chemotherapy-induced apoptosis and a multidrug-resistance (MDR) phenotype, mainly mediated by P-glycoprotein (P-gp), contribute to chemotherapy failure in hematologic malignancies. To study apoptosis-regulating factors in acute myeloid leukemia (AML), we investigated cell samples of adults with de novo AML by flow cytometry for constitutive expression levels of the apoptosis-related molecules CD95 (n ‫؍‬ 135), Bcl-2 (n ‫؍‬ 131), and Bax (n ‫؍‬ 66), as well as spontaneous apoptosis in vitro (n ‫؍‬ 104) and susceptibility to anti-CD95-induced apoptosis (CD95 sensitivity) (n ‫؍‬ 93). We correlated these findings with P-gp function as detected by the rhodamine123-efflux test (n ‫؍‬ 121), immunophenotype, FAB morphology, cytogenetics, and clinical data of the examined patients. Immature FAB M0/1 AML cells expressed significantly more Bcl-2 (P Ͻ 0.0002) and less CD95 (P Ͻ 0.0003) compared with AML cells of the more mature FAB M2-5 subtypes. No maturation-dependent difference in Bax expression was observed. FAB M2-5 AML cells were more susceptible to anti-CD95-induced apoptosis (P Ͻ 0.008) and showed a lower P-gp function (P Ͻ 0.002) than FAB M0/1 AML cells. Leukemic cells of AML patients who achieved a complete remission (CR) after induction chemotherapy expressed less Bcl-2 than nonresponder (NR) (69 CR, 23 NR; P ‫؍‬ 0.05). CR was associated with a higher extent of spontaneous apoptosis in vitro (58 CR, 17 NR; P‫)50.0؍‬ and a tendency towards a higher CD95 expression (73 CR, 23 NR; P ‫؍‬ 0.08) compared to NR. CR also correlated with a low P-gp function (70 CR, 21 NR; P ‫؍‬ 0.008) and a tendency towards CD34 negativity (73 CR, 23 NR; P ‫؍‬ 0.08). No correlation between Bax expression and response to induction chemotherapy (49 CR, 12 NR) was observed. In stepwise logistic regression analyses, P-gp function and the extent of spontaneous apoptosis in vitro as well as CD95 sensitivity but not Bcl-2, CD95, Bax, and CD34 expression levels emerged as significant markers for response to induction chemotherapy. We conclude that the constitutive expression of CD95 and Bcl-2, as well as CD95 sensitivity and P-gp function but not constitutive Bax expression depend on the maturation stage of leukemic cells in adult de novo AML. P-gp function, the extent of spontaneous apoptosis in vitro and CD95 sensitivity are more predictive for response to induction chemotherapy in adult de novo AML than the constitutive expression levels of the apoptosis-related molecules CD95, Bcl-2 and Bax.
Introduction
Chemotherapy failure due to drug resistance of leukemic cells is a major problem in the treatment of acute myeloid leukemia (AML). Several cellular drug resistance mechanisms in AML have been described. [1] [2] [3] [4] Among these, the so-called multidrug-resistance (MDR) phenotype, mainly mediated by the efflux pump P-glycoprotein (P-gp) is the most intensively investigated mechanism so far. [5] [6] [7] [8] [9] [10] [11] [12] In the last few years, it became obvious that the expression and function of molecules involved in the regulation (eg Bcl-2, Bax [13] [14] [15] ) or in the induction (eg CD95 (Fas/APO-1)-antigen [16] [17] [18] ) of apoptosis are also important factors for tumor cell survival and resistance to chemotherapy. [19] [20] [21] Several studies observed a correlation between constitutive Bcl-2 expression and response to chemotherapy in AML, [22] [23] [24] [25] and constitutive CD95 expression in AML has been correlated with response to induction chemotherapy. 26, 27 Myelomonocytic differentiation of normal hematopoietic progenitor cells is associated with changes in the expression levels of Bcl-2 family members and CD95. CD34
+ve hematopoietic progenitor cells showed a low CD95 expression and function, coincubation with IFN␥ and TNF␣ increased CD95 expression levels and susceptibility to anti-CD95-induced apoptosis of these cells. 28 , 29 An increase in CD95 expression levels during granulocytic and monocytic differentiation was observed. 30 Mature monocytes and granulocytes both expressed CD95. Granulocytes, however, were more sensitive to anti-CD95 induced apoptosis than monocytes. 31 CD34
+ve progenitor cells expressed Bcl-2 in a bimodal distribution: CD34 +ve CD38 −ve progenitor cells had lower Bcl-2 expression levels than CD34 +ve CD38 +ve progenitor cells. 32, 33 Bcl-2 expression was higher in monocytes than in granulocytes. The lack of constitutive Bcl-2 expression may be responsible for the rapid apoptotic cell death of granulocytes after growth factor withdrawal. 31 Stem cells showed a low Bax expression, which was upregulated during ex vivo expansion with growth factors. 32 In AML, Bcl-2 expression was higher in immature, CD34 +ve AML than in more mature, CD34
−ve AML cells 22, 24, 34 and correlated with P-gp expression. 35 In several studies, high Bcl-2 expression levels correlated with a poor response to chemotherapy in AML. [22] [23] [24] [25] However, a recently published study failed to confirm these data. 36 AML cells undergoing spontaneous apoptosis in vitro exhibited low Bcl-2 and high Bax levels, whereas nonapoptotic AML cells had high Bcl-2 and low Bax levels. 37 The extent of spontaneous apoptosis in vitro correlated with the response to induction chemotherapy in AML. 38 So far, CD95 expression and function have been investigated only in a relatively small series of patients. One study (n = 64) revealed a higher CD95 expression in more differentiated FAB subtypes (FAB M2-5) than in the immature FAB M1 subtype, 26 whereas another study (n = 30) did not observe any correlation between CD95 expression levels and FAB subtypes. 27 In both studies, complete remission after induction chemotherapy was associated with higher CD95 expression levels compared to non-responders. 26, 27 Two studies examined the sensitivity of AML cells to anti-CD95-induced apoptosis: leukemic cells of 14 of 24 (58%) examined AML cases, 26 and nine of 14 (64%) childhood AML cases 39 were sensitive to anti-CD95-induced apoptosis. To our know-ledge, no study as yet has investigated the correlation between CD95 function, maturation stage and response to chemotherapy in AML. Therefore, we investigated a larger series of adult de novo AML cell samples as to their CD95 expression and function, and determined its relationship to other possible drug resistance mechanisms in AML, such as Bcl-2 and Bax expression, spontaneous apoptosis in vitro, and P-gp function. We correlated these findings with the maturation stage (immunophenotype, FAB morphology) and cytogenetic data. In multiparameter analyses, we determined the predictive value of the drug resistance parameters investigated for the response to induction chemotherapy in adult de novo AML.
Materials and methods

Patients
We examined either freshly obtained or cryopreserved bone marrow or peripheral blood samples from 135 adults with de novo AML. Diagnosis of AML was made morphologically due to FAB criteria 40 and immunologically according to EGIL recommendations. 41 All samples contained more than 90% leukemic cells based on morphological criteria. Of 106 patients (included in the German multicenter AMLCG-86/92 trials 42 ), the response to daunorubicin-and cytosin-arabinoside-based induction chemotherapy and initial laboratory parameters (WBC, platelet count, lactate dehydrogenase) were available for correlation with the experimental data ( Table 1) . 18 patients (Ͻ60 years of age, n = 14; у60 years of age, n = 4) were included in the AMLCG-86 trial and 88 patients (Ͻ60 years of age: n = 54, у60 years of age: n = 34) in the AMLCG-92 trial. No differences between freshly obtained and prior cryopreserved cell samples were seen for the investigated parameters.
Immunophenotyping
Leukemic cells from heparinized bone marrow or peripheral blood samples were isolated by Ficoll-Hypaque (Pharmacia Biotech, Freiburg, Germany) density gradient centrifugation, and cell-surface antigens were detected by a panel of monoclonal antibodies either by a direct or indirect immunofluo- M0 (n = 6), M1 (n = 20), M2 (n = 37), M3 (n = 3), M4 (n = 24), M5 (n = 15) Cytogenetic risk groups good (n = 4), intermediate (n = 33), poor (n = 9) Response to induction early death (n = 10), chemotherapy complete remission (n = 73), non-response (n = 23) rescence assay as previously described. 43, 44 Cell samples were analyzed by flow cytometry (FACScan; Becton-Dickinson, San Diego, CA, USA) using the Cell-Quest-software program (Becton Dickinson). Cell samples were considered positive for a specific antigen if the antigen was expressed on at least 20% of the leukemic cells (20 cut-off level). [43] [44] [45] Expression analysis of CD95, Bcl-2 and Bax by flow cytometry CD95 expression was determined using the PE-conjugated anti-CD95 monoclonal antibody DX2 46 (Pharmingen, San Diego, CA, USA). Nonspecific binding due to Fc␥-receptors, especially in AML with myelomonocytic differentiation, was blocked by preincubation of the cells with polyclonal rabbit serum (Gibco BRL, Paisley, UK). Non-viable cells were excluded from analysis by propidium iodide (PI) staining (Sigma, Deisenhofen, Germany). For analysis of intracellular Bcl-2 and Bax expression, cells were fixed and permeabilized using a fixation-permeabilization kit 47 (An der Grub, Kaumburg, Austria) following the manufacturer's instructions. Bcl-2 antigen was detected by the FITC-conjugated anti-Bcl-2 monoclonal antibody 124 48 (Dako, Hamburg, Germany). Bax expression analyses was later included in our already ongoing study, therefore Bax expression levels were analyzed in only 66 cell samples by indirect immunofluorescence using polyclonal rabbit-anti-human antibody I-19 raised against synthetic peptide sequences 32 (Santa Cruz, CA, USA) and FITClabelled goat-anti-rabbit-antibody (Medac, Hamburg, Germany) as second layer. FITC-and PE-conjugated irrelevant mouse antibodies were used as negative controls for CD95 and Bcl-2 expression analysis. As negative control for Bax expression analysis, cells were stained with Bax antibody in the presence of the blocking synthetic peptide (provided by the manufacturer, Santa Cruz) at saturation conditions (10 g of peptide vs 1 g of antibody) as determined from peptide titration experiments (data not shown). Antigen expression distribution in individual cell samples was largely homogeneous and quantified as relative fluorescence intensity (RFI), determined by the ratio of median fluorescence intensity of cells stained for either CD95, Bcl-2, or Bax to median fluorescence intensity of the corresponding negative controls.
39,49
Cell culture and apoptosis assays
To assess spontaneous apoptosis in vitro, 0.5 × 10 6 cells/well were cultured for 20 h at 37°C in 96-well microtiter plates (Nunc, Roskilde, Denmark) in RPMI 1640 (Biochrom, Berlin, Germany) standard medium containing 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin (Gibco BRL). To investigate the CD95-mediated effects, leukemic cells were incubated with 0.2 g/10 5 cells of anti-CD95 monoclonal antibody CH-11 (IgM; Immunotech, Marseille, France) which was shown to crosslink the CD95 proteins on the cell surface directly. 50 For negative control, cells were incubated with irrelevant control antibodies. All tests were performed in duplicate. Sufficient cell material was available from 104 patients to assess spontaneous apoptosis in vitro and from 93 patients to investigate CD95-mediated apoptotic effects.
To determine the extent of spontaneous and anti-CD95-induced apoptosis after 20-24 h culture, cells were stained with FITC-conjugated AnnexinV 51 and PI using the AnnexinV- cells/sample. The extent of specific CD95-mediated apoptosis (in %) was assessed by a formula as described elsewhere: 49, 52 (CD95-mediated apoptosis − spontaneous apoptosis) × 100 (100 − spontaneous apoptosis) CD95-mediated apoptosis is the percentage of apoptotic cells/sample in the presence of the anti-CD95 moab and spontaneous apoptosis is the percentage of apoptotic cells/sample in the presence of the irrelevant control moab or medium alone. 49, 52 For a series of cell samples, we examined in parallel with AnnexinV-staining, apoptotic DNA fragmentation by determining the percentage of PI-stained leukemic cells with subdiploid DNA content and reduced forward scatter by flow cytometry as previously described. 49 As both methods gave comparable results, we did further studies with the AnnexinVmethod alone, as it was the more convenient method for practical technical reasons.
Detection of P-glycoprotein function
P-gp function was investigated using the rhodamine123 (rh123) efflux test as described elsewhere. 53 Briefly, cells were stained with rh123 (0.5 g/ml) (Sigma), incubated either with or without verapamil (5 M) for 2 h in RPMI medium at 37°C, and then analyzed by flow cytometry. Non-viable cells were excluded from analysis by propidium iodide staining. Cell samples were considered P-gp positive if more than 10% of the cells stained with rh123 alone revealed a lower rh123-fluorescence intensity as compared with cells coincubated with verapamil in the corresponding control sample. 53 
Cytogenetics
Chromosome analyses were performed on metaphases from short term (24 h, 48 h) cultures of pretreatment bone marrow and/or peripheral blood cells. Cell cultivation and chromosome preparation was carried out according to standard protocols. G-banding was used and the chromosomes interpreted according to ISCN (1995) nomenclature. 54 Patients were grouped into three different risk categories: good, t(8;21), inv(16)/t(16;16), t(15;17); intermediate, normal karyotype, other abnormalities; poor: −5/5q−, −7/7q−, 11q23-abnormalities, inv(3)/t(3;3), t(9;22), t(6;9), 17p-abnormalities, complex aberrant karyotype (three or more numerical or structural abnormalities).
Statistical analysis
Differences in the expression levels of CD95, Bcl-2, and Bax as well as the extent of spontaneous apoptosis between the immunologic subgroups (eg CD34
+ve vs CD34
−ve
) and FAB subtypes (M0/1 vs M2-M5) were evaluated by the MannWhitney U test. Differences in the susceptibility to anti-CD95 induced apoptosis and rh123-efflux were evaluated using chisquare-test (Pearson coefficient). The expression levels of CD95, Bcl-2 and Bax were correlated with the extent of spontaneous apoptosis in vitro and anti-CD95 induced apoptosis in individual cell samples by bivariate correlation (Spearman correlation coefficient r s ).
Univariate analyses of the experimental findings with response to induction chemotherapy were performed using either the Mann-Whitney U test (CD95, Bcl-2, Bax expression levels, extent of spontaneous apoptosis in vitro) or chi-square test (P-gp function, CD34 expression, susceptibility to anti-CD95 induced apoptosis). Multivariate analyses of these experimental parameters with therapy response was performed by stepwise logistic regression. All statistical analyses were done with the SPSS software program (version 6.1.3).
Results
Constitutive CD95, Bcl-2 and Bax expression levels in adult de novo AML
Cell samples of adults with de novo AML (n = 135) were analyzed for CD95 expression. Relative CD95 surface expression ranged between 1.1 and 35.2 RFI (mean RFI 7.1 ± 4.6). 131 cell samples of adults with de novo AML were analyzed for Bcl-2 expression. Relative intracellular Bcl-2 expression ranged between 1.0 and 12.4 RFI (mean RFI 2.9 ± 1.6). Sixtysix cell samples of adults with de novo AML were analyzed for Bax expression. Relative intracellular Bax expression ranged between 1.3 and 14.8 RFI (mean RFI 5.5 ± 3.0). Figure 1 shows representative examples for CD95, Bcl-2 and Bax expression in adult de novo AML.
Extent of spontaneous apoptosis in vitro and susceptibility to anti-CD95 induced apoptosis in adult de novo AML
Cell samples of adults with de novo AML (n = 104) could be analyzed for their extent of spontaneous apoptosis in vitro as described in Materials and methods. Spontaneous apoptosis in vitro ranged between 6 and 85% (mean 41 ± 19%) apoptotic cells/sample. Ninety-three cell samples of adults with de novo AML were analyzed for their susceptibility to anti-CD95 induced apoptosis (CD95 sensitivity) as described in Materials and methods. CD95 specific apoptosis/sample ranged between 0 and 85% (mean 19 ± 22%). Fifty of 93 (54%) cell samples revealed at least 10% CD95-sensitive cells/sample. CD95 expression levels correlated only weakly to the extent of anti-CD95 induced apoptosis in individual cell samples (r s = 0.3; n = 93; P Ͻ 0.002). No correlation between CD95 sensitivity and Bcl-2 or Bax expression levels was observed. 
P-glycoprotein function in adult de novo AML
Cell samples of adults with de novo AML (n = 121) were analyzed for their P-gp function as described in Materials and methods. The rh123-efflux positive cells/sample ranged between 0 and 90% (mean 18 ± 24%). Forty-nine of 121 (40%) cell samples revealed more than 10% rh123-efflux 
Correlation of apoptosis parameters and P-gp function with the maturation stage of the examined AML cells
Morphological FAB subtypes of 125 examined patients were available for correlation with the investigated parameters. More mature FAB M2-5 subtypes revealed a significantly higher CD95 expression (P Ͻ 0.0003) and a higher CD95 sensitivity (P Ͻ 0.008) than immature FAB M0/1 subtypes (Table  2) . High CD95 expression levels in AML were associated with a more mature immunophenotype characterized by a low CD34 expression (P Ͻ 0.0009) and a high expression of the myelomonocytic differentiation markers CD15 (P Ͻ 0.0004), CD65s (P Ͻ 0.002), CD14 (P Ͻ 0.004), and CD64 (P Ͻ 0.03) ( Table 3) . Only CD34 expression (P Ͻ 0.0008) but not CD15, CD65s, CD14 and CD64 expression significantly correlated with CD95 sensitivity in adult de novo AML (Table 3) . Bcl-2 expression but not Bax expression correlated with maturation stage in adult de novo AML: immature FAB M0/1 subtypes revealed a higher relative Bcl-2 expression than more mature FAB M2-5 subtypes (P Ͻ 0.0002) ( Table 2 ). High Bcl-2 expression levels in AML were associated with an immature immunophenotype as characterized by a high CD34 expression (P Ͻ 0.0001) and a low expression of the myelomonocytic differentiation markers CD15 (P Ͻ 0.0001), CD65s (P Ͻ 0.0001), CD14 (P Ͻ 0.0001) and CD64 (P Ͻ 0.0002) ( Table 3 ). For Bax expression levels, no significant correlation with FAB subtypes or immunophenotype was seen (Tables 2  and 3 ). There was a tendency to a higher extent of spontaneous apoptosis in vitro in more mature than immature AML cell samples. However, only CD34 expression significantly correlated with the extent of spontaneous apoptosis in adult de novo AML (P Ͻ 0.01) ( Table 3) . P-glycoprotein function correlated with maturation stage in adult de novo AML: immature FAB M0/1 subtypes revealed a higher P-gp function than more mature FAB M2-5 subtypes (P Ͻ 0.002) ( Table 2) . High P-gp function in AML was associated with an immature immunophenotype characterized by a high CD34 expression (P Ͻ 0.00001) and a low expression of the myelomonocytic differentiation markers CD15 (P Ͻ 0.03), CD65s (P Ͻ 0.008), CD14 (P Ͻ 0.03) and CD64 (P Ͻ 0.002) ( Table 3) .
Correlation of the apoptosis parameters and P-gp function with cytogenetic data
Cytogenetic data of 58 patients were available for correlation with the investigated parameters. Cytogenetic risk groups were defined as shown in Materials and methods. Leukemic cells of patients in the poor cytogenetic risk group were more often P-gp positive (P = 0.003), expressed more CD34 (P = 0.005) and less CD95 (P = 0.02) than leukemic cells of patients in the good/intermediate cytogenetic risk group (Table 4) .
Correlation of the apoptosis parameters and P-gp function with clinical data
In univariate analyses, complete remission (CR) after induction chemotherapy correlated with a lower Bcl-2 expression (69 CR, 23 NR; P = 0.05), a higher extent of spontaneous apoptosis (58 CR, 17 NR; P = 0.05), a lower P-gp function (70 CR, 21 NR; P = 0.008), and a tendency towards a higher CD95 expression (73 CR, 23 NR; P = 0.08) compared to nonresponders (NR). NR was associated with a lower CD95-sensitivity compared to CR, however, this difference was not statistically significant. No correlation between constitutive Bax expression and response to induction chemotherapy (49 CR, 12 NR) was observed (Table 5 ). In separate univariate analyses for patients р60 years and patients Ͼ60 years, the prognostic value for response to induction chemotherapy of Bcl-2, P-gp function, the extent of spontaneous apoptosis in vitro and Detection of spontaneous apoptosis in vitro and anti-CD95 induced apoptosis in AML by AnnexinV-staining.
CD95 sensitivity markedly differed between the two age groups (Table 6 ). We found no significant differences for CD95, Bcl-2 and Bax expression levels, functional P-gp activity and for the extent of spontaneous apoptosis in vitro as well as anti-CD95 induced apoptosis between these two different age groups, neither analyzing only patients with either known CR or NR to induction chemotherapy (n = 96; 62 patients р60 years, 34 patients Ͼ60 years), nor analyzing all patients examined (n = 135; 81 patients р60 years, 54 patients Ͼ60 years) (data not shown). In stepwise logistic regression analyses, P-gp function, the extent of spontaneous apoptosis in vitro and CD95 sensitivity emerged as significant predictive markers for response to induction chemotherapy in adult de novo AML (Table 7) . No correlation between the experimental data and initial laboratory parameters (WBC, platelet count, LDH) was found (data not shown). 
Discussion
In this study, we investigated the expression of the apoptosisrelated molecules CD95, Bcl-2 and Bax, the extent of spontaneous apoptosis in vitro, and the susceptibility to anti-CD95 induced apoptosis in adult de novo AML. We correlated these parameters with P-gp function, immunophenotype, FAB morphology, cytogenetics, and clinical data of the patients.
We found a maturation-dependent CD95 expression and CD95 function in adult AML. More mature AML cells expressed more CD95 and were more susceptible to anti-CD95-induced apoptosis than immature AML cells. In accordance with the findings of Iijima et al, 26 we observed a higher CD95 expression in more mature FAB subtypes compared to immature FAB subtypes. However, in contrast to our results, the studies of Iijima et al 26 and Min et al 27 did not show any correlation between CD95 and CD34 expression. This may be partly due to different antibodies used in the studies. Another reason may be that different AML cell samples were included in the studies: Min et al 27 found 47% CD95 +ve AML cell samples, whereas Iijima et al 26 found 83% CD95 +ve AML cell samples (у20% CD95 +ve cells/sample). In two studies, 14 of 24 (58%) examined AML cases, 26 and nine of 14 (64%) childhood AML cases 39 were sensitive to anti-CD95 induced apoptosis. In our series, 50 of 93 (54%) cell samples revealed at least 10% CD95-sensitive cells/sample demonstrating that primary AML cells are more susceptible to anti-CD95 induced apoptosis compared to ALL cells. 49, 52 Immature AML cells were less susceptible to anti-CD95 induced apoptosis than more mature AML cells (Tables 2 and 3 ). Based on these findings, we conclude that the differences in CD95 expression and CD95 function of AML cells resemble the maturation-dependent increase in CD95 expression and CD95 function of normal myeloid progenitor cells. 28, 29, 33 It is still controversial whether interactions between CD95 and CD95 ligand play a major role in chemotherapy-induced apoptosis in acute leukemia. Most of the studies so far were done with leukemic cell lines. Some authors found that the CD95-signalling pathway is important for drug-induced apoptosis, [55] [56] [57] whereas other investigators failed to define any role for CD95-CD95 ligand interactions in drug-induced apoptosis. 58, 59 Our results, which demonstrate a correlation between CD95 expression, function, and response to induction chemotherapy may imply an involvement of the CD95 pathway in chemotherapy-induced apoptosis in AML. Interestingly, CD95 sensitivity in our study seems to correlate especially with response to induction chemotherapy in the patient group Ͼ60 years (Table 6 ). This result supports the hypothesis that prognostic parameters differ with age in adult AML. Functional P-gp activity was shown to be a more important prognostic parameter for older than younger adult AML patients. 60 In contrast, bcl-2 mRNA expression levels discriminated prognostic groups in AML patients Ͻ60 years but not in older patients. 25 Our results confirm these previous findings (Table 6 ). Therefore, despite the relatively small number of examined patients, our results suggest that CD95 sensitivity may be an important prognostic parameter for response to induction chemotherapy, especially in the AML patient group Ͼ60 years (Table 6) . However, further studies of primary leukemic cells are necessary to determine the prognostic value of CD95 expression and function in AML. The correlation with cell cycle state may be especially relevant, as it was shown that CD95-mediated apoptosis was induced in primary AML cells specifically entering G1B compartment. 39 Moreover, monitoring of CD95 expression and CD95 sensitivity during chemotherapy in vivo may lead to further insights into the role of the CD95 pathway in drug-induced apoptosis in acute myeloid leukemia cells.
In our study, constitutive Bcl-2 expression levels in adult AML correlated with maturation stage and response to induction chemotherapy. These findings correspond to the results of previous studies.
22 -25 In accordance with two recently published studies, we observed no correlation between Bax expression and response to chemotherapy. 36, 61 However, it was shown that AML cells undergoing spontaneous apoptosis in vitro revealed low Bcl-2 and high Bax levels, whereas nonapoptotic AML cells had high Bcl-2 and low Bax levels. 37 In our study, no clear correlation between Bcl-2 expression levels and the extent of spontaneous apoptosis in vitro in individual cell samples was observed (r s = −0.2; n = 100, P = 0.07). No correlation was found between Bax expression levels and the extent of spontaneous apoptosis in vitro (r s = 0.1; n = 52, P = 0.6). The intracellular localization of Bax may be more important for the apoptotic behavior of the individual cell than the expression levels alone, as it was shown that upon induction of apoptosis, Bax moves from the cytosol to mitochondria. 62, 63 Our findings, that spontaneous apoptosis in vitro is a significant prognostic marker for response to induction chemotherapy, are consistent with a recently published study on 39 Table 2 Expression levels of CD95, Bcl-2 and Bax, CD95 sensitivity, extent of spontaneous apoptosis in vitro and P-gp function in adult de novo AML: correlation with FAB morphology CD95 n P-value 
Table 3
Expression levels of CD95, Bcl-2 and Bax, CD95 sensitivity, extent of spontaneous apoptosis in vitro and P-gp function in adult de novo AML: correlation with immunophenotype CD95 n P-value (n = 38) 35% ± 20% (n = 7) 0.47 CD95 sensitivity (% of CD95-sensitive cell samples) 53% (n = 34) 29% (n = 7) 0.24 P-glycoprotein function (% of P-gp pos cell samples) 26% (n = 42) 78% (n = 9) 0.003 CD34 expression (% of cell samp у20% CD34 exp) 30% (n = 46) 75% (n = 12) 0.005
For definition of cytogenetic risk groups see Materials and methods; CD95 sensitivity, number of samples with у10% CD95-sensitive cells/number of samples tested (% of samples); P-gp function, number of samples with Ͼ10% rh123 efflux positive cells/number of samples tested (% of samples).
Table 5
Correlation with response to induction chemotherapy: univariate analyses 
Table 6
Correlation with response to induction chemotherapy: univariate analyses for patients р60 years and patients Ͼ60 years
Response to induction chemotherapy P Complete remission Non-responder CD95 expression (mean RFI) р60 ys: 7.5 ± 3.8 (n = 50) 5.6 ± 3.1 (n = 12) 0.11 Ͼ60 ys: 6.9 ± 3.8 (n = 23) 5.8 ± 2.6 (n = 11) 0.40 Bcl-2 expression (mean RFI) р60 ys:
6.7 ± 4.2 (n = 15) 5.6 ± 1.8 (n = 6) 0.94 Extent of spontaneous apoptosis (mean % of apoptotic р60 ys: 43% ± 17% (n = 40) 31% ± 26% (n = 10) 0.04 cells/sample) Ͼ60 ys: 44% ± 16% (n = 18) 38% ± 17% (n = 7) 0.55 CD95 sensitivity (% of CD95-sensitive cell samples) р60 ys: 46% (n = 39) 50% (n = 8) 0.84 Ͼ60 ys: 67% (n = 15) 0% (n = 6) 0.006 P-glycoprotein function (% of Pgp pos cell samples) р60 ys: 35% (n = 48) 60% (n = 10) 0.14 Ͼ60 ys: 32% (n = 22) 73% (n = 11) 0.03 CD34 expression (% of cell samples у20% CD34 exp) р60 ys: 36% (n = 50) 58% (n = 12) 0.16 Ͼ60 ys: 35% (n = 23) 55% (n = 11) 0.27 Poor cytogenetic risk group (% of cell samples) р60 ys:
CD95 sensitivity, number of samples with у10% CD95-sensitive cells/number of samples tested (% of samples); P-gp function, number of samples with Ͼ10% rh123 efflux positive cells/number of samples tested (% of samples).
AML patients, which has shown a significant correlation between the extent of spontaneous apoptosis in vitro and response to induction chemotherapy. 38 The authors of this study hypothesized that measurement of spontaneous apoptosis in AML may be more predictive for prognosis than the assessment of individual signals that influence apoptosis (eg bcl-2, p53), because it evaluates the cumulative effect of all signals that influence programmed cell death. Our results support this hypothesis: multivariate analyses show that the extent of spontaneous apoptosis in vitro and the susceptibility to anti-CD95-induced apoptosis are more predictive for response to chemotherapy compared with the expression levels of the apoptosis-related molecules CD95, Bcl-2 and Bax (Table 7) . Unfortunately, it is often impossible to analyze all these functional parameters to the full extent due to lack of cell material. The strong prognostic significance of the P-gp function in our series is in accordance with several studies on the influence of P-gp expression and function on therapy response and prognosis in AML. 6, 9, 10, 12, 64, 65 In our series, P-gp function was more predictive for response to chemotherapy compared to the expression levels of the apoptosis-related molecules CD95, Bcl-2 and Bax (Table 7) . Recently, it was shown that P-gp inhibits CD95-induced apoptosis. 66 In our series, P-gp +ve AML cell samples were significantly less sensitive to CD95-induced apoptosis than P-gp −ve AML cell samples (12/36 (33%) vs 31/50 (62%); P Ͻ 0.009). Therefore, P-gp function of immature, CD34
+ve AML cells may contribute to their lower CD95 sensitivity compared to more mature, CD34
−ve AML cells. However, we found only a weak correlation between P-gp function and CD95 sensitivity in individual cell samples (r s = −0.2; n = 86; P Ͻ 0.04).
As the detection of P-gp is still quite difficult from a methodological point of view, these findings stress the need of standardized P-gp detection methods. 67, 68 From our own experience, functional P-gp detection is superior to detection of P-gp antigen expression by monoclonal antibodies (unpublished observations).
Specific cytogenetic aberrations in AML correlate with therapy response, 69-71 P-gp expression, 70 and maturational stage. 72 It was speculated that specific cytogenetic aberrations may influence the apoptotic behaviour of AML cells. 73 In myeloid leukemic cell lines with t(8;21), the AML1/ETO fusion protein was shown to activate bcl-2 transcription. 74 However, in accordance with a recently published study, the two patients with t(8;21) AML included in our study showed no increase in Bcl-2 expression. 75 We suggest that specific cytogenetic abnormalities within the poor cytogenetic risk group are associated with an immature, drug-resistant phenotype with high Bcl-2 expression, low CD95 expression and function, as well as strong P-gp function (Table 4) . Whether specific cytogenetic aberrations directly influence the expression and function of these apoptosis-related parameters has to be examined in detail.
It was suggested that mechanisms leading to cell proliferation sensitizes the cell to programmed cell death at the same time. 76 Therefore, in addition to mechanisms leading to an increased cell proliferation, an activation of anti-apoptotic mechanisms in tumor cells should be postulated. 77 In AML, a maturation arrest at an early, immature stage of cell differentiation might be one important strategy of leukemic cells to maintain the anti-apoptotic mechanisms of normal stem cells. Thus, this relatively resistant immature phenotype to different inducers of apoptotic cell death may lead to the survival of the leukemic cells despite an increased proliferative activity. We put forward the hypothesis that the expression patterns of CD95 and Bcl-2 of AML cells, their extent of spontaneous apoptosis in vitro, and their susceptibility to anti-CD95 induced apoptosis, as well as their P-gp function, contribute to an immature drug-resistant phenotype in AML. Functional studies of apoptotic behavior in vitro are more predictive for response to induction chemotherapy in AML than the expression levels of apoptosis-related molecules. Further prospective studies investigating apoptotic mechanisms in AML in vitro and the monitoring of apoptosis-related parameters during chemotherapy-induced apoptosis in vivo are necessary to understand better the importance of these mechanisms for drug resistance in AML.
